Form4insider filings, from the source

SEC Form 4 · accession 0001140361-18-024219

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
May 14, 2018
Accepted (ET)
May 16, 2018 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMay 14, 2018M7,500$1.184A190,207D
Common StockMay 14, 2018S100$132.58D190,107D
Common StockF2,F3May 14, 2018S2,000$134.1845D188,107D
Common StockF2,F4May 14, 2018S2,050$135.0827D186,057D
Common StockF2,F5May 14, 2018S1,525$136.2166D184,532D
Common StockF2,F6May 14, 2018S1,558$137.2763D182,974D
Common StockF2,F7May 14, 2018S167$137.8319D182,807D
Common StockF2,F8May 14, 2018S100$139.0017D182,707D
Common StockMay 15, 2018M7,500$1.184A190,207D
Common StockF2,F9May 15, 2018S700$133.1065D189,507D
Common StockF2,F10May 15, 2018S300$134.4067D189,207D
Common StockF2,F11May 15, 2018S1,000$135.828D188,207D
Common StockF2,F12May 15, 2018S400$136.72D187,807D
Common StockF2,F13May 15, 2018S3,297$138.3521D184,510D
Common StockF2,F14May 15, 2018S1,803$138.8883D182,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F15$1.184May 14, 2018M7,500D—Nov 14, 2023Common Stock7,50022,190D
Employee Stock Option (right to buy)F15$1.184May 15, 2018M7,500D—Nov 14, 2023Common Stock7,50014,690D

Explanation of responses